EGFR and cancer: Since some cancers overexpress certain receptors and its mediation is normally associated with other effectors, such as EGFR, the sole study of mAChRs is not enough to establish a possible treatment or a unique novel therapeutic target; for instance, with nicotinic receptors, data are confirming the activation of the PI3K/AKT/MAPK pathway after nicotinic receptor stimulation; therefore, a synergetic effect after stimulating both receptors should be important to approach and to consider [45,46].